Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768040 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00768040 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT00768040, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema
Interventions
- DRUG Placebo
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768040
The ClinicalTrials.gov registry entry for NCT00768040 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00768040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768040 about?
NCT00768040 is a clinical study titled "Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema". To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema
What is the current status of trial NCT00768040?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-09. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00768040?
The interventions under investigation include: Placebo (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00768040?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.